Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Cancer
Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer
Patients with localised prostate cancer can be treated by radical prostatectomy (prostate gland removal surgery) or radiotherapy.
- Trial name
- CaNCaP02 (NCT02064608)
- Testing
- AZD2014
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Prostate Cancer
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.
- Trial name
- DARIUS (NCT05346848)
- Testing
- Association of darolutamide and EBRT, Association of ADT and EBRT
- Where
- 10 sites in France
- Volunteers
- 62 people
- Sponsor
- Institut Bergonié
Adenocarcinoma of the Prostate, Prostate Cancer
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
Giving diindolylmethane, a substance found in cruciferous vegetables, may help doctors learn more about how diindolylmethane is used by the body.
- Conditions
- Adenocarcinoma of the Prostate, Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT00450229
- Testing
- diindolylmethane, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer
Stereotactic ablative body radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), is a specialized form of radiotherapy used to treat prostate cancer with five treatments over two weeks, compared with a conventional…
- Trial name
- NCT03159676
- Testing
- Proton beam
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca
Prostate Cancer (Adenocarcinoma)
REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)
The goal of this study is to evaluate the recovery of erectile function at six months after hormonal therapy cessation in male patients affected by advanced prostate cancer and undergoing radiotherapy.
- Trial name
- REDI-CaP (NCT07302451)
- Testing
- Combined Androgen Deprivation Therapy with Relugolix and Image-Guided Stereotactic Body Radiotherapy (SBRT)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute, Naples
Low or Intermediate Risk Prostate Cancer
Phase I Study MR-guided SBRT to PCa
1) investigate the feasibility, tolerance, and safety of dose escalation via MR-guided stereotactic body radiation therapy and simultaneous integrated boost to the dominant intraprostatic lesions (DILs), 2) to assess the…
- Trial name
- MRgRTPCa (NCT03935308)
- Testing
- MR guided Linear Accelerator
- Where
- United States
- Sponsor
- Henry Ford Health System
Prostate Cancer, Adenocarcinoma of the Prostate
Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate
This pilot phase II trial studies docetaxel and prednisone in treating patients with newly diagnosed stage I-II prostate cancer undergoing prostatectomy.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- 2007-5904 (NCT00598858)
- Testing
- Docetaxel, Prednisone
- Sponsor
- John P. Fruehauf
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more…
- Trial name
- NCT00067015
- Testing
- bicalutamide, goserelin acetate, assessment of therapy complications
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
This phase II trial studies how well gallium Ga 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/computed tomography (CT) works in detecting regional nodal…
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT03113617
- Testing
- Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy.
- Trial name
- NCT00002723
- Testing
- suramin
- Where
- 27 sites in United States, South Africa
- Volunteers
- 390 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with intermediate or high risk prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03368547
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma, Radiation Toxicity
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
Hypo-Combi Trial: A Prospective Phase I/II Study of Combined Hypofractionated External Beam Radiation Therapy (EBRT) plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) for Intermediate/High Risk Prostate Cancer
- Trial name
- Hypo-Combi (NCT05003752)
- Testing
- External beam radiation therapy, High-dose-rate brachytherapy, Goserelin 10.8 mg
- Where
- Cyprus
- Volunteers
- 40 people
- Sponsor
- German Oncology Center, Cyprus
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Prostate Cancer
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
RATIONALE: Calcitriol and dexamethasone may slow the growth of prostate cancer cells. PURPOSE: This randomized phase II trial is studying how well giving calcitriol together with dexamethasone before radical prostatectomy works…
- Trial name
- NCT00084864
- Testing
- calcitriol, dexamethasone, clinical observation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer, Quality of Life
Functional Outcomes and QoL in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by RARP
The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This database investigates the status after robot assisted laparoscopic prostatectomy (RALP) in prostate cancer patients.
- Conditions
- Prostate Cancer, Quality of Life, Erectile Function, Urinary Function
- Trial name
- NCT03790995
- Testing
- Robot assisted laparoscopic prostatectomy
- Where
- 25 sites in Belgium
- Volunteers
- 9,235 people
- Sponsor
- KU Leuven
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer
Short-term Efficacy of Transperineal Laser Ablation (TPLA) with Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an interventional pilot study.
- Trial name
- NCT04045756
- Testing
- Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Rome Tor Vergata
Prostate Cancer
Cost-utility of Focal HIFU vs Prostatectomy
Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer
- Trial name
- EMERHIT (NCT05710861)
- Testing
- F-HIFU, Radical Prostatectomy
- Where
- 20 sites in France, Guadeloupe
- Volunteers
- 346 people
- Sponsor
- University Hospital, Bordeaux
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center